Breast Cancer Screening and Diagnostic Techniques Market Size Share and Industry Outlook to 2028

SKU: DMMD4115 | Last Updated On: Jan 20 2022 | No. of Pages: 180 | Available Formats

> Global Breast Cancer Screening and Diagnostic Techniques Market Expected to reach a high CAGR By 2028: DataM Intelligence

Global Breast Cancer Screening and Diagnostic Techniques Market is Segmented By Cancer Type (HER2-enriched, Luminal A, Luminal B, Triple-negative/basal-like), By Screening and Diagnostic Type (Clinical Breast Exam, Breast Imaging Modalities, Biopsy), By End-user (Hospitals & Clinics, Cancer Centers, Ambulatory Surgical Centers, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2021-2028

 

Market Overview

The global breast cancer screening and diagnostic techniques market is estimated to reach at a high CAGR during the forecast period (2021-2028).  

Breast cancer screening is carried out to detect cancer in its early stages and ensure the timely treatment to the patients.  Early diagnosis is a key to a successful breast cancer treatment. Breast cancer can be diagnosed early by screening tests like yearly mammograms, CT scans, and MRI. Once the symptoms are visually detectable, an individual is advised to undergo a diagnostic test to confirm the suspects of breast cancer.

Source: DataM Intelligence Analysis (2020)

Market Dynamics

The breast cancer screening and diagnostic techniques market growth is driven by the rising prevalence of breast cancer coupled with the emergence of novel therapies, increasing awareness about the early detection of breast cancer, and increasing government initiatives and support. Early detection of cancer also helps in increasing the survival rate, better life quality, and improved treatment options. Moreover, increased intensive research and development in the field of cancer, technological advancements are key factors to drive the growth of the market.

The rising prevalence of breast cancer coupled with the rise in the emergence of new technologies in early screening and diagnosis is expected to drive the global breast cancer screening and diagnostic techniques market growth

The incidence of breast cancers is proliferating. According to the World Health Organization (WHO) scenario, breast cancer is the second most cancer occurring among women. It affects nearly 2.1 million women each year. According to the American Cancer Society, around 281,550 women are projected to be diagnosed with breast cancer in 2021, and 43,600 women are predicted to die from breast cancer in the US. According to Cancer Treatment Centers of America, women above 60 years of age are more likely to be diagnosed and only about 10% to 15% of cases occur in women younger than 45 years of age.

In addition, the rise in the emergence of new technologies in early screening and diagnosis for breast cancer is also driving the growth of the breast cancer diagnostics market globally. For instance, on July 10th, 2019, Arizona-based SimonMed Imaging announced its implementation of the first U.S. Food and Drug Administration (FDA)-cleared artificial intelligence (AI) program for significantly enhancing early breast cancer detection for 3-D mammography. The AI program, called ProFound AI for digital breast tomosynthesis (DBT), was developed by iCAD Inc.

Growing demand for technologically advanced products is expected to drive the global breast cancer screening and diagnostic techniques market growth

The growing demand for technologically advanced products that can enable better accuracy, speed, and cost-effectiveness is likely to be the dominant growth factor over the forecast period. For instance, the introduction of Direct-To-Consumer (DTC) testing in the field of cancer diagnostics. The first DTC test, introduced in 2018 by 23andMe, received U.S. FDA approval for BRCA testing. It is one of the first DTC tests for the BRCA gene mutations that increase the risk of breast and ovarian cancers. In April 2019, Hologic, Inc. launched the Trident® HD specimen radiography system, a next-generation solution that delivers enhanced image quality, improved workflow and instant sample verification during breast-conserving surgeries and stereotactic breast biopsies.

Besides, the increasing reimbursement and insurance coverage are expected to increase the adoption of testing. Government agencies are approving different tests for nationwide reimbursement. Medicaid, Medicare, and third-party payer benefit plans in the U.S. cover the cost of genetic testing. Genetic tests, such as BRCA1 and BRCA2, are reimbursed by most health plans for individuals with a family history of cancer, which has led to a rise in the number of tests being carried out.

Costly follow-ups for diagnosis, limited availability coupled with the stringent regulatory framework are likely to hamper the market growth

However, costly follow-ups for diagnosis, limited availability and stringent regulatory framework are some of the factors hampering the growth of the breast cancer screening and diagnostic technique market globally. For instance, mammography costs around $200 and approx. 50% of women are poorly diagnosed. There is also limited access to current cancer screening methods in Eastern Europe, Asia and Africa due to the high cost of diagnostic imaging equipment outlays. High false-positive cancer diagnosis rates and indeterminate mammograms requiring follow-up with MRI, 3D mammography, and biopsies are challenges to the market for breast screening and diagnostics.

Market Industry Analysis

PEST Analysis:

Source: DataM Intelligence Analysis (2020)

 

COVID-19 Impact Analysis

The COVID-19 pandemic has negatively impacted healthcare systems globally and also on the market growth. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the Ongoing clinical trials too. However, the situation is expected to improve gradually.

Segment Analysis

The mammography segment is expected to hold the largest share in this market segment

Mammograms are the most widely used tests to screen breast cancer. Since mammography is the standard gold technique used to screen breast cancer, governments and other healthcare organizations worldwide are taking initiatives to provide women between 50 and 75 access to mammography screening. A mammogram is an x-ray of the breast that can reveal benign or malignant abnormalities. It is obtained by applying a small dose of radiation through the breast post-compression between two plates to produce an x-ray image. Mammograms can be utilized for both screening and diagnosis. Mammogram screening is performed as an attempt to detect any early signs of breast cancer, even before symptoms occur, to decrease mortality by early diagnosis. Mammography facilities in the United States and its territories (including military bases) are subject to the Mammography Quality Standards Act (MQSA). The act requires annual inspections and accreditation every three years through an FDA-approved body. Key players are collaborating to innovate new technological tests to diagnose breast cancer. For instance, on July 25th, 2019, Hologic partnered with mammography information solutions provider MagView to develop Unifi EQUIP, an automated solution that will facilitate compliance with the U.S. Food and Drug Administration’s (FDA) Enhancing Quality Using the Inspection Program (EQUIP) guidance. This increases the global demand for mammography. Digital breast tomosynthesis can increase the diagnostic accuracy of mammography and is used for the assessment of equivocal or suspicious mammography findings. Other modalities, such as ultrasound and contrast-enhanced magnetic resonance imaging (MRI), play an important role in breast cancer diagnostics, staging, and follow-up.

The hospitals and clinics segment is expected to hold the largest share in this market segment

The hospitals and clinics segment dominated the market for breast cancer screening and diagnostics market. The increasing hospitalization of patients and the growing burden of the disease are expected to propel the segment's growth. After the screening test, patients undergo a biopsy for confirmatory testing in hospitals. For instance, in 2020, there were 2.3 million women diagnosed with breast cancer and 685 000 deaths globally. As of the end of 2020, there were 7.8 million women alive who have been diagnosed with breast cancer in the past 5 years, making it the world's most prevalent cancer. Moreover, PET, CT, and MRI are used to check disease progression and assess the effectiveness of cancer treatment.

Further, governments have increased the number of initiatives to provide various services, such as reimbursement for diagnostic tests. Many healthcare institutions work with laboratories to integrate different tests, such as mammography, ultrasound, and MRI.

Source: DataM Intelligence Analysis (2020)

Geographical Analysis

North America region holds the largest market share of the global breast cancer screening and diagnostic techniques market

North America dominates the breast cancer screening and diagnostics market due to rising breast cancer cases and increasing technological advancements for cancer diagnosis. For instance, about 1 in 8 U.S. women (about 12%) will develop invasive breast cancer throughout their lifetime. In 2019, an estimated 268,600 new cases of invasive breast cancer were expected to be diagnosed in women in the U.S., along with 62,930 new cases of non-invasive (in situ) breast cancer. About 2,670 new cases of invasive breast cancer are expected to be diagnosed in men in 2019. A man's lifetime risk of breast cancer is about 1 in 883.

In addition, increasing initiatives taken by the manufacturers to create awareness about breast cancer are driving the market's growth in this region. For instance, in July 2019, Fujifilm Medical Systems USA has launched a nationwide effort to enhance access to breast cancer screening and raise awareness about the importance of early disease detection. Called "Aspire to Be Fearless," the 18-month, the 48-state campaign features a mobile mammography bus that will travel around the country to educate local communities and offer mammograms. New product developments, acquisitions, collaborations, and regional expansions are some of the key strategic initiatives major players undertake to maintain stability in the market. For instance, In July 2019, Exact Sciences Corp and Genomic Health Inc. entered into a definitive agreement in which these companies will create a leading global cancer diagnostics company. The combined company will offer two of the strongest and fastest-growing brands in cancer diagnostics, Cologuard and Oncotype DX.

Source: DataM Intelligence Analysis (2020)

Competitive Landscape

The global breast cancer screening and diagnostic techniques market is highly competitive with the presence of global companies.  Some of the key players which are contributing to the growth of the market include Allengers, Myriad Genetics, Inc, Siemens Healthcare GmbH, GE Healthcare, Hologic Inc, Abbott Laboratories, QIAGEN, Paragon Biosciences LLC, Quest Diagnostics Incorporated. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, In July 2019, Paragon Biosciences launched the seventh portfolio company, Qlarity Imaging LLC, which was founded to harness the value of artificial intelligence (AI) to improve medical outcomes.

Breast Cancer Screening and Diagnostics Techniques Market Key Companies to Watch

QIAGEN

Overview: QIAGEN, founded in 1984, is a German provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. Currently, with 5,300 employees. Founded by the three young scientists, Metin Colpan, Karsten Henco, and Jürgen Schumacher, and their doctoral supervisor Detlev Riesner, their goal was to establish a research outfit supplying products for molecular biological research.

Product Portfolio: The company portfolio includes Oncology, Liquid Biopsy, Infectious disease, Next-generation sequencing, Molecular biology research, Genomic services, Digital PCR.

Key developments:

In May 2019, QIAGEN launched its first FDA-approved companion diagnostic for PIK3CA biomarkers to enhance precision medicine in breast cancer

Why Purchase the Report?

  • Visualize the composition of the breast cancer screening and diagnostic techniques market segmentation by screening and diagnostic type, cancer type, end-user and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in the breast cancer screening and diagnostic techniques market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of breast cancer screening and diagnostic techniques market-level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global breast cancer screening and diagnostic techniques market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages. 

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Trending Topics

Contrast Media Injectors Market

Mammography Detectors Market

Table of Contents

  1. Global Breast Cancer Screening and Diagnostic Techniques Methodology and Scope

    1. Research Methodology
    2. Research Objective and Scope of the Report
  2. Global Breast Cancer Screening and Diagnostic Techniques Market – Market Definition and Overview

  3. Global Breast Cancer Screening and Diagnostic Techniques Market – Executive Summary

    1. Market Snippet by Cancer Type
    2. Market Snippet by Screening and Diagnostic Type
    3. Market Snippet by End-user
    4. Market Snippet by Region
  4. Global Breast Cancer Screening and Diagnostic Techniques Market – Market Dynamics

    1. Market Impacting Factors
      1. Drivers
        1. The rising prevalence of breast cancer coupled with the rise in the emergence of new technologies in early screening and diagnosis
        2. Growing demand for technologically advanced products
      2. Restraints:
        1. Costly follow-ups for diagnosis, limited availability coupled with stringent regulatory framework
      3. Opportunity
      4. Impact Analysis
  5. Global Breast Cancer Screening and Diagnostic Techniques Market – Industry Analysis

    1. Porter's Five Forces Analysis
    2. PEST Analysis
    3. Supply Chain Analysis
    4. Epidemiology
    5. Pricing Analysis
    6. Regulatory Analysis
    7. Reimbursement Analysis
    8. Unmet Needs
  6. Global Breast Cancer Screening and Diagnostic Techniques Market – COVID-19 Analysis

    1. Analysis of Covid-19 on the Market
      1. Before COVID-19 Market Scenario
      2. Present COVID-19 Market Scenario
      3. After COVID-19 or Future Scenario
    2. Pricing Dynamics Amid Covid-19
    3. Demand-Supply Spectrum
    4. Government Initiatives Related to the Market During Pandemic
    5. Manufacturers Strategic Initiatives
    6. Conclusion 
  7. Global Breast Cancer Screening and Diagnostic Techniques Market – By Cancer Type

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
      2. Market Attractiveness Index, By Cancer Type
    2. HER2-enriched*
      1. Introduction
      2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    3. Luminal A
    4. Luminal B
    5. Triple-negative/basal-like
  8. Global Breast Cancer Screening and Diagnostic Techniques Market – By Screening and Diagnostic Type

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Screening and Diagnostic Type Segment
      2. Market Attractiveness Index, By Screening and Diagnostic Type Segment
    2. Clinical Breast Exam*
      1. Introduction
      2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
      3. Low Dose X-rays
        1. Mammography
    3. Breast Imaging Modalities
      1. Magnetic Field
        1. Magnetic Resonance Imaging
        2. Dynamic Contrast Enhanced MRI (DCE-MRI)
        3. Magnetic Resonance Spectroscopy
        4. Diffusion-Weighted Imaging
        5. MR Elastography (MRE)
    4. Biopsy
      1. Nuclear Medicine
        1. Positron Emission Tomography (PET)
        2. Positron Emission Tomography conjugated with computed Tomography (PET-CT)
        3. Sentinel lymph node biopsy (SLNB)
        4. Breast Specific Gamma Imaging (BSGI)
  9. Global Breast Cancer Screening and Diagnostic Techniques Market – By End-user

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user Segment
      2. Market Attractiveness Index, By End-user Segment
    2. Hospitals & Clinics*
      1. Introduction
      2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    3. Cancer Centers
    4. Ambulatory Surgical Centers
    5. Others
  10. Global Breast Cancer Screening and Diagnostic Techniques Market – By Region

    1. Introduction
      1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
      2. Market Attractiveness Index, By Region
    2. North America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Screening and Diagnostic Type
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. U.S.
        2. Canada
        3. Mexico
    3. Europe
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Screening and Diagnostic Type
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Germany
        2. U.K.
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
    4. South America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Screening and Diagnostic Type
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Brazil
        2. Argentina
        3. Rest of South America
    5. Asia Pacific
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Screening and Diagnostic Type
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. China
        2. India
        3. Japan
        4. Australia
        5. Rest of Asia Pacific
    6. Middle East and Africa
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Screening and Diagnostic Type
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
  11. Global Breast Cancer Screening and Diagnostic Techniques Market – Competitive Landscape

    1. Key Developments and Strategies
    2. Company Share Analysis
    3. Product Benchmarking
    4. Key Companies to Watch
    5. Company with disruptive technology
    6. Start Up Companies
  12. Global Breast Cancer Screening and Diagnostic Techniques Market- Company Profiles

    1. QIAGEN*
      1. Company Overview
      2. Product Portfolio and Description
      3. Key Highlights
      4. Financial Overview
    2. Allengers
    3. Myriad Genetics, Inc
    4. Siemens Healthcare GmbH
    5. GE Healthcare
    6. Hologic Inc
    7. Abbott Laboratories
    8. Paragon Biosciences LLC
    9. Quest Diagnostics Incorporated(*LIST NOT EXHAUSTIVE)
  13. Global Breast Cancer Screening and Diagnostic Techniques Market – DataM  

    1. Appendix
    2. About Us and Services
    3. Contact Us

List of Tables & Figures

List of Tables

Table 1 Global Breast Cancer Screening and Diagnostic Techniques Market Value, By Screening and Diagnostic Type, 2020, 2024 & 2028 ($ Million)

Table 2 Global Breast Cancer Screening and Diagnostic Techniques Market Value, By Cancer Type, 2020, 2024 & 2028 ($ Million)

Table 3 Global Breast Cancer Screening and Diagnostic Techniques Market Value, By End-User, 2020, 2024 & 2028 ($ Million)

Table 4 Global Breast Cancer Screening and Diagnostic Techniques Market Value, By Region, 2020, 2024 & 2028 ($ Million)

Table 5 Global Breast Cancer Screening and Diagnostic Techniques Market Value, By Screening and Diagnostic Type, 2020, 2024 & 2028 ($ Million)

Table 6 Global Breast Cancer Screening and Diagnostic Techniques Market Value, By Screening and Diagnostic Type, 2019-2028 ($ Million)

Table 7 Global Breast Cancer Screening and Diagnostic Techniques Market Value, By Cancer Type, 2020, 2024 & 2028 ($ Million)

Table 8  Global Breast Cancer Screening and Diagnostic Techniques Market Value, By Cancer Type, 2019-2028 ($ Million)

Table 9 Global Breast Cancer Screening and Diagnostic Techniques Market Value, By End-User, 2020, 2024 & 2028 ($ Million)

Table 10 Global Breast Cancer Screening and Diagnostic Techniques Market Value, By End-User, 2019-2028 ($ Million)

Table 11 Global Breast Cancer Screening and Diagnostic Techniques Market Value, By Region, 2020, 2024 & 2028 ($ Million)

Table 12 Global Breast Cancer Screening and Diagnostic Techniques Market Value, By Region, 2019-2028 ($ Million)

Table 13 North America Breast Cancer Screening and Diagnostic Techniques Market Value, By Screening and Diagnostic Type, 2019-2028 ($ Million)

Table 14 North America Breast Cancer Screening and Diagnostic Techniques Market Value, By Cancer Type, 2019-2028 ($ Million)

Table 15 North America Breast Cancer Screening and Diagnostic Techniques Market Value, By End-User, 2019-2028 ($ Million)

Table 16 North America Breast Cancer Screening and Diagnostic Techniques Market Value, By Country, 2019-2028 ($ Million)

Table 17 South America Breast Cancer Screening and Diagnostic Techniques Market Value, By Screening and Diagnostic Type, 2019-2028 ($ Million)

Table 18 South America Breast Cancer Screening and Diagnostic Techniques Market Value, By Cancer Type, 2019-2028 ($ Million)

Table 19 South America Breast Cancer Screening and Diagnostic Techniques Market Value, By End-User, 2019-2028 ($ Million)

Table 20 South America Breast Cancer Screening and Diagnostic Techniques Market Value, By Country, 2019-2028 ($ Million)

Table 21 Europe Breast Cancer Screening and Diagnostic Techniques Market Value, By Screening and Diagnostic Type, 2019-2028 ($ Million)

Table 22 Europe Breast Cancer Screening and Diagnostic Techniques Market Value, By Cancer Type, 2019-2028 ($ Million)

Table 23 Europe Breast Cancer Screening and Diagnostic Techniques Market Value, By End-User, 2019-2028 ($ Million)

Table 24 Europe Breast Cancer Screening and Diagnostic Techniques Market Value, By Country, 2019-2028 ($ Million)

Table 25 Asia-Pacific Breast Cancer Screening and Diagnostic Techniques Market Value, By Screening and Diagnostic Type, 2019-2028 ($ Million)

Table 26 Asia-Pacific Breast Cancer Screening and Diagnostic Techniques Market Value, By Cancer Type, 2019-2028 ($ Million)

Table 27 Asia-Pacific Breast Cancer Screening and Diagnostic Techniques Market Value, By End-User, 2019-2028 ($ Million)

Table 28 Asia-Pacific Breast Cancer Screening and Diagnostic Techniques Market Value, By Country, 2019-2028 ($ Million)

Table 29 Middle East & Africa Breast Cancer Screening and Diagnostic Techniques Market Value, By Screening and Diagnostic Type, 2019-2028 ($ Million)

Table 30 Middle East & Africa Breast Cancer Screening and Diagnostic Techniques Market Value, By Cancer Type, 2019-2028 ($ Million)

Table 31 Middle East & Africa Breast Cancer Screening and Diagnostic Techniques Market Value, By End-User, 2019-2028 ($ Million)

Table 32 QIAGEN: Overview

Table 33 QIAGEN: Product Portfolio

Table 34 QIAGEN: Key Developments

Table 35 Allengers: Overview

Table 36 Allengers: Product Portfolio

Table 37 Allengers: Key Developments

Table 38 Myriad Genetics, Inc: Overview

Table 39 Myriad Genetics, Inc: Product Portfolio

Table 40 Myriad Genetics, Inc: Key Developments

Table 41 Siemens Healthcare GmbH: Overview

Table 42 Siemens Healthcare GmbH: Product Portfolio

Table 43 Siemens Healthcare GmbH: Key Developments

Table 44 GE Healthcare: Overview

Table 45 GE Healthcare: Product Portfolio

Table 46 GE Healthcare: Key Developments

Table 47 Hologic Inc: Overview

Table 48 Hologic Inc: Product Portfolio

Table 49 Hologic Inc: Key Developments

Table 50 Abbott Laboratories: Overview

Table 51 Abbott Laboratories: Product Portfolio

Table 52 Abbott Laboratories: Key Developments

Table 53 Paragon Biosciences LLC: Overview

Table 54 Paragon Biosciences LLC: Product Portfolio

Table 55 Paragon Biosciences LLC: Key Developments

Table 56 Quest Diagnostics Incorporated: Overview

Table 57 Quest Diagnostics Incorporated: Product Portfolio

Table 58 Quest Diagnostics Incorporated: Key Developments

List of Figures

Figure 1 Global Breast Cancer Screening and Diagnostic Techniques Market Share, By Screening and Diagnostic Type, 2020 & 2028 (%)

Figure 2 Global Breast Cancer Screening and Diagnostic Techniques Market Share, By Cancer Type, 2020 & 2028 (%)

Figure 3 Global Breast Cancer Screening and Diagnostic Techniques Market Share, By End-User, 2020 & 2028 (%)

Figure 4 Global Breast Cancer Screening and Diagnostic Techniques Market Share, By Region, 2020 & 2028 (%)

Figure 5 Global Breast Cancer Screening and Diagnostic Techniques Market Value, 2019-2028 ($ Million)

Figure 6 Global Breast Cancer Screening and Diagnostic Techniques Market Y-o-Y Growth, By Screening and Diagnostic Type, 2020-2028 (%)

Figure 7 Clinical Breast Exam: Global Breast Cancer Screening and Diagnostic Techniques Market Value, 2019-2028 ($ Million)

Figure 8 Breast Imaging Modalities: Global Breast Cancer Screening and Diagnostic Techniques Market Value, 2019-2028 ($ Million)

Figure 9 Biopsy: Global Breast Cancer Screening and Diagnostic Techniques Market Value, 2019-2028 ($ Million)

Figure 10 Global Breast Cancer Screening and Diagnostic Techniques Market Y-o-Y Growth, By Cancer Type, 2020-2028 (%)

Figure 11 Luminal A: Global Breast Cancer Screening and Diagnostic Techniques Market Value, 2019-2028 ($ Million)

Figure 12 Luminal B: Global Breast Cancer Screening and Diagnostic Techniques Market Value, 2019-2028 ($ Million)

Figure 13 Triple-negative/basal-like: Global Breast Cancer Screening and Diagnostic Techniques Market Value, 2019-2028 ($ Million)

Figure 14 HER2-enriched: Global Breast Cancer Screening and Diagnostic Techniques Market Value, 2019-2028 ($ Million)

Figure 15 Global Breast Cancer Screening and Diagnostic Techniques Market Y-o-Y Growth, By End-User, 2020-2028 (%)

Figure 16 Hospitals: Global Breast Cancer Screening and Diagnostic Techniques Market Value, 2019-2028 ($ Million)

Figure 17 Ambulatory Surgical Centers: Global Breast Cancer Screening and Diagnostic Techniques Market Value, 2019-2028 ($ Million)

Figure 18 Cancer Centers: Global Breast Cancer Screening and Diagnostic Techniques Market Value, 2019-2028 ($ Million)

Figure 19 Clinics: Global Breast Cancer Screening and Diagnostic Techniques Market Value, 2019-2028 ($ Million)

Figure 20 Others: Global Breast Cancer Screening and Diagnostic Techniques Market Value, 2019-2028 ($ Million)

Figure 21 Global Breast Cancer Screening and Diagnostic Techniques Market Y-o-Y Growth, By Region, 2020-2028 (%)

Figure 22 North America Breast Cancer Screening and Diagnostic Techniques Market Value, 2019-2028 ($ Million)

Figure 23 North America Breast Cancer Screening and Diagnostic Techniques Market Share, By Screening and Diagnostic Type, 2020 & 2028 (%)

Figure 24 North America Breast Cancer Screening and Diagnostic Techniques Market Share, By Cancer Type, 2020 & 2028 (%)

Figure 25 North America Breast Cancer Screening and Diagnostic Techniques Market Share, By End-User, 2020 & 2028 (%)

Figure 26 North America Breast Cancer Screening and Diagnostic Techniques Market Share, By Country, 2020 & 2028 (%)

Figure 27 South America Breast Cancer Screening and Diagnostic Techniques Market Value, 2019-2028 ($ Million)

Figure 28 South America Breast Cancer Screening and Diagnostic Techniques Market Share, By Screening and Diagnostic Type, 2020 & 2028 (%)

Figure 29 South America Breast Cancer Screening and Diagnostic Techniques Market Share, By Cancer Type, 2020 & 2028 (%)

Figure 30 South America Breast Cancer Screening and Diagnostic Techniques Market Share, By End-User, 2020 & 2028 (%)

Figure 31 South America Breast Cancer Screening and Diagnostic Techniques Market Share, By Country, 2020 & 2028 (%)

Figure 32 Europe Breast Cancer Screening and Diagnostic Techniques Market Value, 2019-2028 ($ Million)

Figure 33 Europe Breast Cancer Screening and Diagnostic Techniques Market Share, By Screening and Diagnostic Type, 2020 & 2028 (%)

Figure 34 Europe Breast Cancer Screening and Diagnostic Techniques Market Share, By Cancer Type, 2020 & 2028 (%)

Figure 35 Europe Breast Cancer Screening and Diagnostic Techniques Market Share, By End-User, 2020 & 2028 (%)

Figure 36 Europe Breast Cancer Screening and Diagnostic Techniques Market Share, By Country, 2020 & 2028 (%)

Figure 37 Asia-Pacific Breast Cancer Screening and Diagnostic Techniques Market Value, 2019-2028 ($ Million)

Figure 38 Asia-Pacific Breast Cancer Screening and Diagnostic Techniques Market Share, By Screening and Diagnostic Type, 2020 & 2028 (%)

Figure 39 Asia-Pacific Breast Cancer Screening and Diagnostic Techniques Market Share, By Cancer Type, 2020 & 2028 (%)

Figure 40 Asia-Pacific Breast Cancer Screening and Diagnostic Techniques Market Share, By End-User, 2020 & 2028 (%)

Figure 41 Asia-Pacific Breast Cancer Screening and Diagnostic Techniques Market Share, By Country, 2020 & 2028 (%)

Figure 42 Middle East & Africa Breast Cancer Screening and Diagnostic Techniques Market Value, 2019-2028 ($ Million)

Figure 43 Middle East & Africa Breast Cancer Screening and Diagnostic Techniques Market Share, By Screening and Diagnostic Type, 2020 & 2028 (%)

Figure 44 Middle East & Africa Breast Cancer Screening and Diagnostic Techniques Market Share, By Cancer Type, 2020 & 2028 (%)

Figure 45 Middle East & Africa Breast Cancer Screening and Diagnostic Techniques Market Share, By End-User, 2020 & 2028 (%)

Figure 46 QIAGEN: Financials

Figure 47 Allengers: Financials

Figure 48 Myriad Genetics, Inc: Financials

Figure 49 Siemens Healthcare GmbH: Financials

Figure 50 GE Healthcare: Financials

Figure 51 Hologic Inc: Financials

Figure 52 Abbott Laboratories: Financials

Figure 53 Paragon Biosciences LLC: Financials

Figure 54 Quest Diagnostics Incorporated: Financials

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Year-End Offer from
DataM Intelligence

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest